MFN2 and neuropathy: In patients with confirmed genetic lipodystrophy, for example, individuals with pathogenic variants in the LMNA gene should engage in close cardiac follow-up given the high reported risk for cardiac disease, especially arrhythmias [12], while those with pathogenic variants in the MFN2 gene are expected to have neuropathy and should undergo neurologic evaluation [42].